Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbSci ( (ABSI) ) has shared an update.
On March 6, 2026, Absci’s board approved amended and restated indemnification agreements for its directors and officers under Delaware law, refining change-of-control definitions, extending coverage for separate counsel in such events, and adding a presumption of good faith for officer indemnitees, while excluding indemnification for certain clawed-back incentive or equity compensation. These updated agreements, which replaced prior forms and were executed by all current directors and officers the same day, are designed to clarify protections for leadership as the company advances its AI-driven drug pipeline and navigates increasing regulatory and governance complexities.
On March 3, 2026, Absci announced that Chief Innovation Officer Andreas Busch will retire effective March 31, 2026, while remaining with the company for two years as a scientific advisor and co-chair of its Scientific Advisory Board, supported by an annual cash retainer, new equity awards, and extended exercise periods on vested stock options. The company simultaneously appointed former Vertex executive Ransi Somaratne as Chief Medical Officer effective March 3, 2026, strengthening clinical leadership to guide the development of Absci’s AI-designed therapeutics, including its flagship ABS-201 program, and signaling a shift from innovation build-out toward late-stage clinical execution.
The most recent analyst rating on (ABSI) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
Overall score is held back primarily by weak financial performance (unprofitability and ongoing cash burn). Technicals are also soft in the near term, and valuation metrics provide limited support due to losses and no dividend. The key offset is a more positive earnings-call outlook driven by ABS-201 pipeline momentum and partnering plans.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci Corporation is a clinical-stage biopharmaceutical company that uses generative artificial intelligence and synthetic biology to design and develop novel biologic therapeutics. Its Integrated Drug Creation platform supports both internal programs and collaborations, with a pipeline that includes ABS-201 for hair regrowth and endometriosis, targeting large unmet medical needs in dermatology and women’s health.
Average Trading Volume: 3,310,235
Technical Sentiment Signal: Sell
Current Market Cap: $389.5M
Find detailed analytics on ABSI stock on TipRanks’ Stock Analysis page.